What Genemarkers does

Genemarkers, LLC is a privately held, certified woman-owned contract research laboratory (CRO) founded in 2007 and headquartered in Kalamazoo, Michigan. The company specializes in genomic and proteomic biomarker testing for the biopharmaceutical and consumer products industries, operating a CLIA-certified, CAP-accredited, and GCLP-compliant laboratory that supports both preclinical/translational research and clinical-trial-stage studies. Its technology stack spans qPCR, RNA sequencing (Illumina), ELISA, Meso Scale Discovery (MSD) multiplex immunoassays, immunohistochemistry, DNA methylation, microbiome testing, and CYP450 pharmacogenomic genotyping, complemented by a fully automated histology platform with quantitative image analysis.

The company's core service lines are organized into Preclinical & Translational Research, Clinical Trial Services (including kitting/sample logistics and PGX genotyping), Consumer Product Testing (CPG), Histology, and Therapeutic Expertise (dermatology, inflammation, and CNS). It offers proprietary gene expression panels (Standard Skin, Environmental Stress, Skin Brightening, Blue Light, Dermal Papilla Cell, and CBD panels) and disease-specific ex vivo tissue models validated for atopic dermatitis and psoriasis research. Notable technical assets include a 52-gene blue light panel published in the International Journal of Cosmetic Science, ex vivo human skin tissue models with verified expression of 30+ AD-specific and 400+ psoriasis-specific biomarkers, and a UVB-validated melanin inhibition assay paired with a 50-gene melanogenesis qPCR panel.

Genemarkers generates revenue through fee-for-service contracts, with study designs and pricing scoped per project after scientific consultation. Distribution is direct-to-business via a Request a Quote / Talk to a Scientist model with global sample logistics. Named enterprise customers include Biocogent (6+ year relationship), Amway, KKT Innovation Labs, and an unnamed herbal extracts/consumer goods ingredient manufacturer. The company is led by founder and CEO Anna Langerveld, PhD, with no institutional investors or parent-company relationships identified.

Name

Genemarkers

Legal name

Genemarkers, LLC

Website

https://genemarkersllc.com

Company type

Private

Founded year

2007

Operating status

Operating

Headcount range

11–50 employees

Short description

Genemarkers is a CLIA-certified, CAP-accredited, GCLP-compliant contract research laboratory in Kalamazoo, Michigan, founded in 2007, providing genomic and proteomic biomarker testing services — including qPCR, RNA-Seq, MSD immunoassays, histology, and proprietary gene expression panels — to biopharmaceutical and consumer product companies for preclinical and clinical trial research.

Ownership category

akta.pro rank

Product category

Contract Research Laboratory Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Testing Laboratories (8734), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA)

akta.pro secondary industries

Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF), Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays) (HLAAAMAC), Proteomics & Biomarker Analytical Testing (HLAGADAG), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Proteomics & Mass Spectrometry Services (HLAGANAB)

Keywords

• Contract research organization
• Biomarker testing services
• Genomic proteomic analysis
• Preclinical translational research
• Consumer product testing

Headquarters

HQ city

Kalamazoo

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain

Revenue model

1. Contract Research Services: Genemarkers operates as a contract research organization (CRO) providing laboratory testing services to pharmaceutical and consumer product companies. Revenue is generated through fee-for-service contracts for preclinical and clinical research, biomarker testing, and regulatory support. Projects are scoped custom with study design consultation.

Distribution channels1 record

Marketing channels5 records

Core offering

Genemarkers is a certified woman-owned contract research laboratory providing genomic and proteomic biomarker testing services to pharmaceutical and consumer product companies. It delivers preclinical, clinical trial, and consumer product testing using molecular biology technologies such as qPCR, RNA sequencing, ELISA, MSD immunoassay, histology, and in vitro/ex vivo skin tissue models.

Product overview

Genemarkers is a certified woman-owned contract research laboratory (founded 2007) offering a unified portfolio of genomic and proteomic biomarker testing services organized across three core service lines: (1) Preclinical & Translational Research Services — covering sample collection kitting, in vitro cell and tissue models, DNA/RNA/protein isolation, genomic biomarker analysis (CYP450 genotyping, mRNA-Seq, Taqman qPCR, DNA methylation, microbiome), protein biomarker analysis (MSD, ELISA, IHC), and computational data analysis; (2) Clinical Trial Services — CAP/CLIA-certified biomarker testing for clinical trials including pharmacogenomic (PGX) genotyping, kitting and sample logistics, and bioinformatics; and (3) Consumer Product Testing (CPG) — biomarker testing for skincare, hair care, and nutraceuticals including safety screening, genomic and protein analysis, tissue challenges, cell/tissue models, clinical skin samples, and tailored Gene Expression Panels (Standard Skin, Environmental Stress, Skin Brightening, Blue Light, Dermal Papilla Cell, and CBD panels). Supporting specialty offerings include Histology Services (H&E, IHC, immunofluorescence, special stains, quantitative image analysis), Dermatology Therapeutic Services (in vitro/ex vivo dermal models, tissue challenges, clinical sample analysis), Inflammation & CNS Services, Ex Vivo Atopic Dermatitis & Psoriasis Tissue Models, and the In Vitro Melanin Inhibition Assay. All services are delivered through a structured study design, execution, and data interpretation process.

Differentiator

Problem solved

Functional benefit

Products and services

• Preclinical & Translational Research Services Comprehensive preclinical and translational research services generating high-quality genomic and proteomic data from in vitro cells, preclinical animal tissue samples, and clinical human samples. Supports IND submissions and early-stage clinical trials, including sample collection kitting, cell and tissue-based in vitro models, DNA/RNA/protein isolation, genomic biomarker analysis (CYP450 genotyping, mRNA-Seq, Taqman qPCR, DNA methylation, microbiome), protein biomarker analysis (MSD, ELISA, IHC), and computational data analysis.
• Clinical Trial Services Genomic and proteomic biomarker testing services supporting clinical trials across multiple therapeutic areas with CAP and CLIA-certified laboratory capabilities. Includes nucleic acid isolation, targeted qPCR, RNA sequencing via Illumina, whole exome sequencing, ELISA, multiplex proteomic panels via MSD, histology and immunohistochemistry, assay development and validation, bioinformatics, and kitting and sample logistics.
• Histology Services End-to-end histology services for pharmaceutical and consumer products industries, delivered on a fully automated high-throughput platform. Includes tissue fixation, embedding, sectioning, H&E staining, immunohistochemistry (single and double label), immunofluorescence, special stains (Herovici, Movat Pentachromie), and quantitative image analysis.
• Dermatology Therapeutic Services Specialized dermal drug development expertise working with in vitro and ex vivo dermal cells, tissues, and clinical samples (skin biopsies and tape strips). Includes 2D and 3D in vitro dermal models, ex vivo skin, wounded tissue and AD/Psoriasis disease models, in vitro tissue challenges (UV, blue light, diesel particulate, wounding, inflammation), and analysis from clinical samples.
• Inflammation & CNS Services Off-the-shelf solutions for evaluating biomarkers to expedite drug discovery across inflammatory and CNS therapeutic conditions. Inflammation services include in vitro cell culture of PBMCs and immune cells, gene/protein cytokine and chemokine panels, clinical serum/plasma/blood analysis, and validated ELISAs. CNS services include neuronal and glial cell culture, complex in vitro models, neurotransmitter pathway gene expression panels, and neuroinflammation protein panels.
• Consumer Product Testing Services (CPG) Consumer product testing solutions for the skincare, hair care, and nutritional industries, applying biomarker technologies to enhance product development and support science-backed claims. Services include safety screening, genomic biomarker analysis, protein biomarker analysis, tissue challenges, cell and tissue models, and clinical skin sample analysis.
• Gene Expression Panels Tailored qPCR-based gene expression panels for skin biology research providing a cost-effective entry into genomics. Available panels include Standard Skin Panel, Environmental Stress Panel, Skin Brightening Panel, Blue Light Panel (52 genes), Dermal Papilla Cell Panel (52 genes), and Cannabinoid (CBD) Panel. Custom panels can be created for specific research areas.
• In Vitro Melanin Inhibition Assay In vitro assay using normal human primary melanocytes to induce and quantitatively measure UV-induced melanin production and melanogenesis under controlled conditions. Supports ingredient screening, efficacy substantiation, comparative testing, dose-response evaluation, and mechanism of action studies, accompanied by a proprietary qPCR panel of 50 biomarker genes.
• Ex Vivo Atopic Dermatitis & Psoriasis Tissue Models Ex vivo tissue models that mimic key components of atopic dermatitis (AD) and psoriasis for preclinical and clinical drug development of topical compounds, with verified expression of over 30 AD-specific and 400 psoriasis-specific gene expression biomarkers. Study endpoints include RNA sequencing, targeted qPCR, ELISA, and immunohistochemistry.
• Pharmacogenomic (PGX) Testing qPCR-based pharmacogenomic genotyping services for clinical trials, enabling patient stratification, dose refinement, and risk reduction. Supports CYP450 genotyping (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, CYP3A4), SNP detection for drug-metabolizing enzymes, and ADME prediction. Processes thousands of samples per week with non-invasive buccal swab collection.
• Ex Vivo Tissue Models (General) Ex vivo human skin tissue models — living skin explants from consenting surgical donors — preserving full tissue architecture including epidermis, dermis, barrier function, extracellular matrix, immune cells, hair follicles, and sebaceous glands. Suitable for AD and psoriasis drug development, inflammation and immunomodulation studies, drug delivery research, safety/toxicity studies, and wound healing research. Compatible with qPCR, RNA-Seq, ELISA, and MSD.
• Kitting & Sample Logistics Collection kitting expertise covering biopsies, tape strips, blood, serum, plasma, buccal swabs and other sample types, with customizable e-manifests and barcoding. Includes a full-time IATA-certified logistics team with on-call customer service, global multi-site distribution, and short- and long-term sample storage.
• Blue Light Testing Service Validated in vitro model for assessing product protection against HEV (blue light), including a gene expression panel of 52 genes specifically impacted by blue light covering oxidative stress, inflammation, and skin aging pathways. Enables clients to assess how their products protect against and repair blue light-induced skin damage.
• Cannabidiol (CBD) Gene Expression Panel Gene expression panel for testing the biological efficacy of CBD extracts and cosmetic formulas containing them. The panel tests the CB1 and CB2 skin receptors and evaluates regulation of over 150 genes in the skin relevant to wound healing, pigmentation, aging, and acne.

Quantifiable outcome

• Nearly 90% of clinical drug development programs fail; genotyping helps reduce risk
• +5 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature7 records

Scale indicators6 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• BioAgilytix Labs: Specialty bioanalytical CRO focused on biomarker testing, immunoassays, and pharmacokinetic/pharmacodynamic analyses for pharma and biotech. Directly comparable to Genemarkers' proteomic and genomic biomarker testing for clinical trials, including MSD and ELISA-based services.
• Celerion: Early-phase clinical CRO with strong bioanalytical and biomarker capabilities supporting pharmaceutical development. Comparable specialty CRO positioning with similar customer base and service mix.
• Frontage Laboratories: CRO providing bioanalytical, preclinical, and clinical laboratory services including genomic and proteomic biomarker testing. Comparable mid-size CRO profile with similar pharma/biotech customer base.

Broad incumbents

• Eurofins Scientific: Global testing services conglomerate with extensive dermatology, cosmetics, and clinical trial bioanalytical capabilities. Overlaps with Genemarkers' qPCR, ELISA, and tissue-based testing but at significantly larger scale and broader portfolio.
• Charles River Laboratories: Major CRO offering preclinical, clinical, and bioanalytical services including biomarker testing for dermatology and inflammation. Competes for the same pharma sponsors seeking validated biomarker assays in clinical trials.
• IQVIA: Largest global CRO with extensive bioanalytical and biomarker laboratories supporting clinical trials. Competes for biomarker testing contracts across therapeutic areas including dermatology.
• Medpace: Mid-to-large CRO with full-service clinical trial capabilities including central lab and biomarker services. Competes for clinical trial biomarker contracts from biotech and pharma sponsors.
• Labcorp Drug Development (formerly Covance): Large CRO with central laboratory capabilities supporting clinical trials including genomic and proteomic testing. Significant overlap with Genemarkers' clinical trial biomarker services.
• SGS: Global testing, inspection, and certification company with cosmetics and life sciences testing divisions. Overlaps with Genemarkers' consumer products testing services and broader analytical testing capabilities.

Regional players

• Intertek: Global quality assurance and testing services provider with cosmetics and personal care testing capabilities. Competes with Genemarkers' CPG testing business for skincare and personal care brand customers.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/genemarkers-biopharma

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Genemarkers